IQVIA leads a fragmented real world evidence solutions market

By AI, Created 1:06 PM UTC, May 20, 2026, /AGP/ – The Business Research Company says the real world evidence solutions market remains highly fragmented, with the top 10 players holding 10% of revenue in 2024 and IQVIA Holdings Inc. leading global sales with 1% share. The report points to low-code workflows, integrated analytics and AI-driven tools as the main competitive moves as demand grows for regulatory-grade evidence and faster clinical decision-making.

Why it matters: - Real world evidence tools are becoming more important as healthcare and life sciences companies look for regulatory-grade evidence, faster analytics and better clinical decision support. - The market’s fragmentation creates room for partnerships, product innovation and regional expansion, but it also raises the bar for data quality, interoperability and compliance.

What happened: - The Business Research Company released its Real World Evidence Solutions Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - IQVIA Holdings Inc. led global sales in 2024 with a 1% market share. - The top 10 players accounted for 10% of total market revenue in 2024. - The report lists major companies including IBM, UnitedHealth Group, Oracle, SAS Institute, ICON, PAREXEL, Syneos Health, Thermo Fisher Scientific, Cognizant, Cegedim Health Data, Medpace, Inovalon, Labcorp Drug Development, Elevance Health, Clarivate, Palantir, Informa, Deloitte, Analysis Group, Symphony Innovation and KMK Consulting.

The details: - IQVIA’s real world evidence and advanced analytics division provides real-world data analytics platforms, healthcare data integration, predictive modeling tools and regulatory-grade evidence generation services. - The market is shaped by moderate barriers tied to data privacy rules, healthcare compliance, multi-source data integration, evidence quality requirements and the need for accuracy, reliability and scalability. - The report identifies low-code workflow tools and integrated analytics platforms as a major trend because they improve processing efficiency, scalability and auditability. - In August 2025, Aetion launched aetion activate, a platform for accelerated real-world data analysis using low-code workflows and hosted coding environments. - Aetion’s platform includes reusable algorithms, built-in data-cleaning tools and an audit-ready analytics environment. - The report names major raw material suppliers as IQVIA, Oracle, IBM, SAS Institute, Microsoft, Google, Amazon Web Services, ICON, Parexel and Syneos Health. - Major wholesalers and distributors listed include McKesson, Cardinal Health, Cencora, Owens & Minor, Medline, Henry Schein, Sinopharm, Shanghai Pharmaceuticals, Zuellig Pharma, PHOENIX Pharma, Movianto, Uniphar, Alliance Healthcare, H. D. Smith, ANDA, CuraScript SD, Walgreens Boots Alliance, Morris & Dickson and AAH Pharmaceuticals. - Major end users include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Kaiser Permanente, University College London Hospitals NHS Foundation Trust, UCSF Health, Mount Sinai Health System, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, St. Jude Children’s Research Hospital, Labcorp, Quest Diagnostics, NHS England, Apollo Hospitals Enterprise, Fortis Healthcare, Medanta, Singapore General Hospital, Cleveland Clinic Abu Dhabi and Ramsay Health Care. - The report says companies are advancing real world evidence solutions for clinical and regulatory decision-making, integrating data platforms to improve evidence accuracy, modernizing evidence infrastructure for observational and post-market research, and using AI-driven analytics to improve accuracy, automation and efficiency. - The report includes a free sample request and the full market report.

Between the lines: - The 1% share held by the leading companies shows a crowded market where scale alone does not dominate outcomes. - Competitive advantage appears to depend more on integration depth, regulatory readiness and the ability to turn messy healthcare data into reproducible evidence. - The emphasis on AI, low-code tools and audit-ready workflows suggests buyers want speed without sacrificing validation.

What’s next: - The report expects strategic collaborations, product innovation and regional expansion to strengthen leading vendors. - Demand for AI-driven decision support and regulatory-grade evidence is likely to keep pushing vendors toward more automated and interoperable platforms. - Market participants are likely to keep investing in analytics infrastructure that supports observational and post-market research.